Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens (Q39472050)

12 September 2017

Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens (English)

1 reference

12 September 2017

Bianca Altvater

1

0 references

Barbara Savoldo

5

object named as

Barbara Savoldo

1 reference

12 September 2017

Sibylle Pscherer

2

1 reference

12 September 2017

Silke Landmeier

3

1 reference

12 September 2017

Sareetha Kailayangiri

4

1 reference

12 September 2017

Heribert Juergens

6

1 reference

12 September 2017

Claudia Rossig

7

1 reference

12 September 2017

18 September 2011

1 reference

Cancer Immunology, Immunotherapy

12 September 2017

1 reference

12 September 2017

61

1 reference

12 September 2017

3

1 reference

12 September 2017

385-396

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-1111-6

12 September 2017

0 references

cites work

Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Clinical implications of PRAME gene expression in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Gammadelta T cells: functional plasticity and heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Natural and synthetic non-peptide antigens recognized by human gamma delta T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Episomal vectors rapidly and stably produce high-titer recombinant retrovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1111-6

10.1007/S00262-011-1111-6

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference